Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Surgical treatment

International Journal of Surgery

Volumn 21, Issue S1, 2015, Pages S1-S3

  Benassai, G ^a   Quarto, G ^a   Perrotta, S ^a   Furino, E ^a   Benassai, G L ^a   Amato, B ^a   Bianco, T ^a   De Palma, G ^a   Forestieri, P ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Long term survival; Pancreatic cancer; Prognostic factors

Indexed keywords

ADULT; AGED; BLOOD TRANSFUSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPERATION DURATION; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SURGICAL MORTALITY; SURVIVAL RATE; ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; ITALY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; ITALY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84940453163     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2015.06.050     Document Type: Review

References (31)

1. Pezzilli R., Uomo G., Gabbrielli A., Zerbi A., Frulloni L., De Rai P., et al. A prospective multicentre survey on the treatment of acute pancreatitis in Italy. Dig. Liver Dis. September 2007, 39(9):838-846.
2. Benassai G., Mastrorilli M., Quarto G., Cappiello A., Giani U., Mosella G. Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir. Ital. May 2000, 52(3):263-270.
3. Castoldi L., De Rai P., Zerbi A., et al. Long term outcome of acute pancreatitis in Italy: results of a multicentre study. Dig. Liver Dis. October 2013, 45(10):827-832.
4. De Rai P., Zerbi A., Castoldi L., Bassi, et al. Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study. HPB November 2010, 12(9):597-604.
5. Benassai G., Mastrorilli M., Quarto G., Cappiello A., Giani U., Forestieri P., Mazzeo F. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J. Surg. Oncol. 2000, 73(4):212-218.
6. Perrone F., Marangolo M., Di Costanzo F., et al. Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori 2005, 91:373-379.
7. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
8. Ferrone C.R., Brennan M.F., Gonen M., et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J. Gastrointest. Surg. 2008, 12:701-706.
9. Crist D.W., Sitzmann J.V., Cameron J.L. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann. Surg. 1987, 206:358-365.
10. Han S.S., Jang J.Y., Kim S.W., et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006, 32:71-75.
11. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J. Gastrointest. Surg. 2000, 4:567-579.
12. Warshaw A.L., Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 1992, 326:455-465.
13. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 pancreati-coduodenectomies for pancreatic cancer: a single-institution experience. J. Gastrointest. Surg. 2006, 10:1199-1210.
14. Mayo S.C., Gilson M.M., Herman J.M., et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J. Am. Coll. Surg. 2012, 214:33-45.
15. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
16. Neoptolemos J.P., Stocken D.D., Bassi C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010, 304:1073-1081.
17. Regine W.F., Winter K.A., Abrams R., et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann. Surg. Oncol. 2011, 18:1319-1326.
18. Fischer M., Matsuo K., Gonen M., et al. Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management. Ann. Surg. 2010, 252:952-958.
19. Lieberman M.D., Kilburn H., Lindsey M., et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann. Surg. 1995, 222:638-645.
20. Pawlik T.M., Laheru D., Hruban R.H., et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann. Surg. Oncol. 2008, 15:2081-2088.
21. Rasheed Z.A., Yang J., Wang Q., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl. Cancer Inst. 2010, 102:340-351.
22. Javle M.M., Gibbs J.F., Iwata K.K., et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann. Surg. Oncol. 2007, 14:3527-3533.
23. Krantz S.B., Shields M.A., Dangi-Garimella S., et al. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J. Surg. Res. 2012, 173:105-112.
24. Lehner P.J., Surman M.J., Cresswell P. Soluble tapasin restores MHC class I expression and function in the tapasin-negative cell line .220. Immunity 1998, 8:221-231.
25. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 2003, 21:807-839.
26. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 2004, 22:1136-1151.
27. Ahmad N.A., Lewis J.D., Ginsberg G.G., et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am. J. Gastroenterol. 2001, 96:2609-2615.
28. Cleary S.P., Gryfe R., Guindi M., et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J. Am. Coll. Surg. 2004, 198:722-731.
29. Conzo G., Circelli L., Pasquali D., Sinisi A., Sabatino L., Accardo G., Renzullo A., Santini L., Salvatore F., Colantuoni V. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 triple mutation of the RET proto-oncogene. Clin. Endocrinol. Oxf. 2012 Dec, 77(6):934-936. 10.1111/j.1365-2265.2012.04412.x.
30. Dicitore A., Caraglia M., Gaudenzi G., et al. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim. Biophys. Acta Rev. Cancer 2014, 1845(1):42-52. 10.1016/j.bbcan.2013.11.003.
31. Conzo G., Tartaglia E., Esposito D., Gambardella C., Mauriello C., Mascolo M., Russo D., Stornaiuolo G., Gaeta G.B., Santini L. Suprarenal solitary fibrous tumor associated with a NF 1 gene mutation mimicking a kidney neoplasm. Implications for surgical management. World J. Surg. Oncol. 2014 Apr 7, 12(1):87. 1-5. 10.1186/1477-7819-12-87.